New technologies for new influenza vaccines

Vaccine

Volumn 30, Issue 33, 2012, Pages 4927-4933

  Shaw, Alan ^a  

^a VaxInnate   (United States)

Author keywords

Attenuated; Cold adapted; Influenza; NS1 deletion; Toll Like Receptors; Vaccine; Virus like particles

Indexed keywords

DNA VACCINE; EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; LIVE VACCINE; M2E VACCINE; PROTEIN M2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; VIRUS VECTOR; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIBODY TITER; CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; EGG; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; MAMMAL CELL; MORBIDITY; MORTALITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TOBACCO; VACCINE PRODUCTION; VIRION; VIRUS LIKE AGENT; VIRUS STRAIN;

ANIMALS; BIOTECHNOLOGY; HUMANS; INFLUENZA VACCINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84862753802     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.095     Document Type: Review

References (76)

1. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 2012, 12(January (1)):36-44. [Meta-Analysis, Research Support, Non-U.S. Gov't, Review].
2. Schild G.C., Pereira M.S., Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bulletin of the World Health Organization 1975, 52(1):43-50.
3. Kilbourne E.D. Future influenza vaccines and the use of genetic recombinants. Bulletin of the World Health Organization 1969, 41(3):643-645.
4. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26(January (4)):552-561.
5. Smorodintsev A.A., Zhdanov V.M. Results and immediate tasks of the study of live influenza vaccine. Voprosy Virusologii 1957, 2(March-April (2)):67-72.
6. Smorodintsev A.A. Basic aspects of the study of live influenza vaccine. Klinicheskaia Meditsina (Mosk) 1962, 40(November):33-39.
7. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25 degrees C. Nature 1967, 213(February (5076)):612-614.
8. Jin H., Lu B., Zhou H., Ma C., Zhao J., Yang C.F., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306(February (1)):18-24.
9. Youil R., Su Q., Toner T.J., Szymkowiak C., Kwan W.S., Rubin B., et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. Journal of Virological Methods 2004, 120(September (1)):23-31. [Comparative Study].
10. Kiseleva I., Su Q., Toner T.J., Szymkowiak C., Kwan W.S., Rudenko L., et al. Cell-based assay for the determination of temperature sensitive and cold adapted phenotypes of influenza viruses. Journal of Virological Methods 2004, 116(March (1)):71-78. [Comparative Study].
11. Palker T., Kiseleva I., Johnston K., Su Q., Toner T., Szymkowiak C., et al. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Research 2004, 105(October (2)):183-194.
12. Cox M.M., Karl Anderson D. Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza and Other Respiratory Viruses 2007, 1(January (1)):35-40. [Review].
13. Cox M.M., Patriarca P.A., Treanor J. FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza and Other Respiratory Viruses 2008, 2(November (6)):211-219. [Multicenter Study, Randomized Controlled Trial, Review].
14. Cox M.M., Hollister J.R. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 2009, 37(June (3)):182-189. [Review].
15. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. The Journal of the American Medical Association 2007, 297(April (14)):1577-1582. [Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't].
16. Treanor J.J., Betts R.F., Smith G.E., Anderson E.L., Hackett C.S., Wilkinson B.E., et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. The Journal of Infectious Diseases 1996, 173(June (6)):1467-1470. [Clinical Trial, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.].
17. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(February (13-14)):1732-1737. [Clinical Trial, Controlled Clinical Trial, Research Support, U.S. Gov't, P.H.S.].
18. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23(December (50)):5751-5759. [Research Support, N.I.H., Extramural].
19. Song H., Wittman V., Byers A., Tapia T., Zhou B., Warren W., et al. In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010, 28(August (34)):5524-5532.
20. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(July (30)):4771-4776.
21. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501. [Research Support, Non-U.S. Gov't].
22. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. Journal of Virology 2011, 85(November (21)):10945-10954.
23. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007, 25(May (21)):4283-4290.
24. Shoji Y., Farrance C.E., Bautista J., Bi H., Musiychuk K., Horsey A., et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza and Other Respiratory Viruses 2011, 6(October):204-210.
25. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(12):e15559. [Clinical Trial, Phase I, Randomized Controlled Trial, Research Support, Non-U.S. Gov't].
26. D'Aoust M.A., Couture M.M., Charland N., Trepanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnology Journal 2010, 8(June (5)):607-619. [Review].
27. Shapira M., Jolivet M., Arnon R. A synthetic vaccine against influenza with built-in adjuvanticity. International Journal of Immunopharmacology 1985, 7(5):719-723. [Comparative Study].
28. McEwen J., Levi R., Horwitz R.J., Arnon R. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 1992, 10(6):405-411.
29. Arnon R., Ben-Yedidia T. Preclinical efficacy of a virus-like particle-based vaccine against avian influenza H5N1. Future Microbiology 2009, 4(June (5)):503-505. [Comment].
30. Ben-Yedidia T., Arnon R. Towards an epitope-based human vaccine for influenza. Human Vaccines 2005, 1(May-June (3)):95-101. [Review].
31. Rudolph W., Ben Yedidia T. A universal influenza vaccine: where are we in the pursuit of this " Holy Grail" ?. Human Vaccines 2011, 7(January (1)):10-11. [Review].
32. Bright R.A., Ross T.M., Subbarao K., Robinson H.L., Katz J.M. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003, 308(April (2)):270-278. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
33. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. Journal of Virology 2011, 85(February (3)):1246-1256. [Research Support, American Recovery and Reinvestment Act, Research Support, N.I.H., Extramural].
34. Treanor J.J., Taylor D.N., Tussey L., Hay C., Nolan C., Fitzgerald T., et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010, 28(December (52)):8268-8274. [Randomized Controlled Trial].
35. Liu G., Tarbet B., Song L., Reiserova L., Weaver B., Chen Y., et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One 2011, 6(6):e20928. [Research Support, Non-U.S. Gov't].
36. Taylor D.N., Treanor J.J., Strout C., Johnson C., Fitzgerald T., Kavita U., et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011, 29(July (31)):4897-4902.
37. Leng J., Stout-Delgado H.W., Kavita U., Jacobs A., Tang J., Du W., et al. Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 2011, 29(October (45)):8147-8155.
38. Lamb R.A., Choppin P.W. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 1981, 112(July (2)):729-737. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.].
39. Lamb R.A., Lai C.J. Conservation of the influenza virus membrane protein (M1) amino acid sequence and an open reading frame of RNA segment 7 encoding a second protein (M2) in H1N1 and H3N2 strains. Virology 1981, 112(July (2)):746-751. [Comparative Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
40. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69(May (3)):517-528. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
41. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of Virology 1988, 62(August (8)):2762-2772. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
42. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerging Infectious Diseases 2006, 12(April (4)):569-574.
43. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27(October (45)):6280-6283. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review].
44. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. Journal of Immunology 2011, 186(January (2)):1022-1031. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't].
45. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Journal of Immunology 2004, 172(May (9)):5598-5605.
46. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(August (23-24)):2993-3003. [Comparative Study].
47. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(January (2)):201-214. [Comparative Study].
48. Turley C.B., Rupp R.E., Johnson C., Taylor D.N., Wolfson J., Tussey L., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29(July (32)):5145-5152. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't].
49. Talbot H.K., Rock M.T., Johnson C., Tussey L., Kavita U., Shanker A., et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010, 5(12):e14442. [Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't].
50. Bianchi E., Liang X., Ingallinella P., Finotto M., Chastain M.A., Fan J., et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. Journal of Virology 2005, 79(June (12)):7380-7388.
51. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(April (5924)):246-251. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.].
52. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 3(12):e3942. [Research Support, Non-U.S. Gov't].
53. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural & Molecular Biology 2009, 16(March (3)):265-273. [Research Support, N.I.H., Extramural].
54. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(August (31)):13701-13706. [Research Support, Non-U.S. Gov't].
55. Graves P.N., Schulman J.L., Young J.F., Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126(April (1)):106-116. [Comparative Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
56. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(November (44)):18979-18984. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't].
57. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1. 10E000 18-10.
58. Garcia-Sastre A., Egorov A., Matassov D., Brandt S., Levy D.E., Durbin J.E., et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998, 252(December (2)):324-330. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.].
59. Kochs G., Garcia-Sastre A., Martinez-Sobrido L. Multiple anti-interferon actions of the influenza A virus NS1 protein. Journal of Virology 2007, 81(July (13)):7011-7021. [Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't].
60. Wacheck V., Egorov A., Groiss F., Pfeiffer A., Fuereder T., Hoeflmayer D., et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. The Journal of Infectious Diseases 2010, 201(February (3)):354-362. [Randomized Controlled Trial, Research Support, Non-U.S. Gov't].
61. Gao Q., Palese P. Rewiring the RNAs of influenza virus to prevent reassortment. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(September (37)):15891-15896. [Research Support, N.I.H., Extramural].
62. Gao Q., Lowen A.C., Wang T.T., Palese P. A nine-segment influenza A virus carrying subtype H1 and H3 hemagglutinins. Journal of Virology 2010, 84(August (16)):8062-8071. [Research Support, N.I.H., Extramural].
63. Co M.D., Orphin L., Cruz J., Pazoles P., Rothman A.L., Ennis F.A., et al. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 2008, 26(April (16)):1990-1998. [Comparative Study, Research Support, N.I.H., Extramural].
64. La Gruta N., Kelso A., Brown L.E., Chen W., Jackson D.C., Turner S.J. Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development. Expert Review of Respiratory Medicine 2009, 3(October (5)):523-537.
65. Goodman A.G., Heinen P.P., Guerra S., Vijayan A., Sorzano C.O., Gomez C.E., et al. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One 2011, 6(10):e25938.
66. Alexander J., Bilsel P., del Guercio M.F., Stewart S., Marinkovic-Petrovic A., Southwood S., et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010, 28(January (3)):664-672. [Research Support, N.I.H., Extramural].
67. McMichael A.J. From influenza to HIV-and back?. Nature Immunology 2007, 8(November (11)):1149-1151. [Biography, Historical Article].
68. Schultz-Cherry S., Dybing J.K., Davis N.L., Williamson C., Suarez D.L., Johnston R., et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278(December (1)):55-59. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.].
69. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007, 25(November (48)):8180-8189. [Research Support, N.I.H., Extramural].
70. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2006, 24(February (8)):1180-1190. [Research Support, Non-U.S. Gov't].
71. Ben-Yehuda A., Ehleiter D., Hu A.R., Weksler M.E. Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection. The Journal of Infectious Diseases 1993, 168(August (2)):352-357. [Research Support, U.S. Gov't, P.H.S.].
72. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005, 23(January (8)):1029-1036. [Clinical Trial, Phase I, Comparative Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.].
73. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clinical Infectious Diseases 2011, 52(January (1)):1-7. [Clinical Trial, Phase I, Research Support, Non-U.S. Gov't].
74. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans. Clinical Infectious Diseases 2012, (March).
75. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009, 27(October (45)):6296-6299. [Research Support, Non-U.S. Gov't].
76. Marazzi I., Ho J.S., Kim J., Manicassamy B., Dewell S., Albrecht R.A., et al. Suppression of the antiviral response by an influenza histone mimic. Nature 2012, 483(March (7390)):428-433.